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ABSTRACT 
This research was carried out to assess the quality and compare the physico-chemical equivalence of twenty 
samples of ciprofloxacin hydrochloride tablets marketed in Kano metropolis using standard analytical methods. 
The physico-chemical and chemical equivalence were assessed through the evaluation of uniformity of weight, 
disintegration test, friability test, assay for percentage concentration, metal impurities, pH and ionic strength. 
The product assay was carried out using UV/Visible spectrophotometric method while atomic absorption 
spectrophotometer was used to determine the possible metal impurities. All the samples complied with the 
official specifications for uniformity of weight, friability test while one sample failed the disintegration test of 
15mins. Eighteen samples conformed to specifications 90% - 110% w/w of stated amount, one sample was 
above the limit, 111.66+0.57% w/w, while another sample was below the limit, 87.65+0.70 w/w. Eighteen of 
the samples evaluated in this study could be regarded as being physico-chemically and chemically equivalent 
while two samples could be regarded as substandard and fake product. All the samples have the metal impurities 
within official specifications except for one which has high concentration of lead. 
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INTRODUCTION  
The World Health Organization (WHO) at 
the International Conference of Primary Health 
Care, Alma Ata 1973, identified the supply of good 
quality essential drugs as one of the basic pre-
requisites for the delivery of health care and thus 
promulgated the WHO certification scheme on the 
quality of pharmaceutical products in international 
commerce. Some 128 countries participated in the 
WHO certification scheme, yet fake, adulterated 
and sub-standard drugs are exported from 
manufacturing countries into the non-
manufacturing developing countries because of the 
conditions of sales. It was in view of this fact that 
World Health Organization (WHO) issued 
guidelines for global standard and requirements for 
the registration, assessment, marketing 
authorization, and quality control of generic 
pharmaceutical products (WHO, 1996, 2005). The 
quality of these drugs and the threat of counterfeit 
pharmaceuticals have been largely ignored 
(Shakoor et al., 1997). There is mounting evidence 
that counterfeit pharmaceuticals pose a serious 
threat to public health, especially in developing 
countries (Pecoul et al., 199).  
Pharmaceutical counterfeiting is a 
pervasive problem, impacting nations of every 
description (Aluba 1994, Graviela, 2001). There 
are many reports of the availability of counterfeited 
medicines, not only in developing countries but 
also in Europe and USA (Shakoor et al., 
1997).Indication shows that there are substandard 
drugs circulating in the market in different 
developing countries, widely reported in Africa, 
Asia and Latin America (Shakoor et al., 
1997).Antibiotics are the most frequently used, 
misused, abused and counterfeited class of drugs 
worldwide (Global Forum, 2002). The presence of 
substandard antibiotics in various parts of Nigeria 
as reported by some authors includes tetracycline 
capsules and ampicillin oral suspension (Aluba, 
1994). This contributed to the problem of 
increasing resistance among previously sensitive 
bacterial species to common antimicrobial agents 
in Nigeria (Philip et al., 2005). The most common 
and widely spread dangers associated with the use 
of substandard antibiotics are waste of resources, 
microbial resistance and the complication of 
diseases (Oliphant and Green, 2002).  
Ciprofloxacin developed by Bayer in 
1981, is the first oral antimicrobial drug with broad 
spectrum activity for treating severe infections 
caused by both gram-negative and gram-positive 
bacteria including pseudomonas spp. and 
staphylococcus spp. (Nayaz et al., 2013). It is one 
of the 4- quinolone carboxylic acid derivatives as 
drug for its chemical activity.  It is relatively non-
toxic, well tolerated and has proven especially 
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useful for oral therapy of chronic gram-negative 
infections such as osteomyelitis and recurrent 
cholangitis, and for acute exacerbations of 
pseudomonas infection in cystic fibrosis (Shahnaz 
et al., 2014). It is soluble in water, slightly soluble 
in methanol, very slightly soluble in ethanol, 
practically insoluble in acetone, ethyl acetate and 
methylene chloride (Susmita et al., 2009). There 
has been a proliferation of different brands of these 
antibiotics in Nigeria, many of which are incredibly 
cheap compared with ciprofloxacin by Bayer 
pharmaceutical limited, hence the need for the 
assessment of their quality (Philip et al., 2005). 
In parts of the world, the evaluation and 
assessment of different brands of Ciprofloxacin 
tablet marketed were reported, (Mai, 2015, Jaman 
et al., 2015, Kholoud, 2009). A good number of 
assessment and evaluation of the quality of 
ciprofloxacin marketed in some Africa countries 
have been reported, (Getu, 2010, Mus’ab et al., 
2010, Tadesse and Shibesi, 2015). Different 
authors have also undertaken various studies in the 
ciprofloxacin available in the Nigerian 
environment, (Ngozi et al., 2007, Bagbi et al., 
2014).  
Nigeria imports a large proportion of its 
pharmaceutical requirements from various regions of 
the world. This has led to indiscriminate dumping of 
fake, adulterated and counterfeit medicines in the 
Nigerian drug market. The problems of fake, 
substandard and counterfeited drugs threaten the 
survival and effective functioning of the society.  
Pharmaceutical tablets are composed of 
number of different materials, each of which is 
designed to improve performance at the targeted site. 
Metallic particles (mostly heavy metals) are common 
contaminants in the pharmaceutical manufacturing 
process, a problem that should be addressed before 
the product is released to market (Mary and Kent, 
2010).   
 Kano drug market has about five thousand 
registered pharmaceutical shops, some in Sabon – 
Gari market while others are located outside the 
market (NAFDAC, 2005). Drugs are distributed 
from the manufacturing companies through the 
medical representatives to the distributors, to the 
retailers and finally to the consumers.  
The aim of the research is to assess the 
quality of the various brands of Ciprofloxacin 
tablets sold in Kano metropolis to ascertaining their 
effectiveness and establishing baseline information 
on the level of substandard ciprofloxacin 
hydrochloride tablets in Kano drug market.  
 
MATERIALS AND METHODS  
Cleaning of Materials  
All glass wares and plastics containers 
used in this work were washed with detergent, 
soaked in potassium dichromate solution then 
washed with tap water and finally rinsed with de 
ionized water and dried in an oven at 
105OC.Wooden spatula was used throughout the 
work. All the salt chemicals used are of analar 
grade and the nitric acid from sigma Aldrich 
(specific gravity-1.42, percentage concentration- 
70%). 
 
Sample Collection  
The samples selected were from three 
drug producing regions of the world; Africa, Asia 
and Europe. Ciprofloxacin hydrochloride tablets 
were purchased from retail outlets mainly from 
private pharmaceutical and drug stores in Kano. 
The drug samples were obtained in their original 
package as supplied by the manufacturers and 
protected from direct sunlight. 
 
Weight Uniformity 
Twenty tablets of each sample were 
individually weighed using an electronic analytical 
balance (model APX – 100 Denver Instrument, 
England). The mean tablet weight and standard 
deviation were calculated. 
 
Friability Test  
The weight of 20 tablets of all the samples 
was taken individually using electronic analytical 
balance, model APX – 100 Denver Instrument, 
England. The tablets were placed in the drum of 
Erweka type TA friability testing machine. The 
machine was switched on and operated at a speed 
of 25 revolutions per minute for four minutes. The 
tablets were dusted and their weight taken again to 
ascertain the percentage friability,             
 
Disintegration Time Test  
To determine disingration time, 900cm3 
distilled water was poured into a 1000cm3 capacity 
beaker and then placed in the disintegration 
machine, (IP STD. Tablet Disintegration Machine, 
Lab Sales Cooperation, New Delhi, India). The 
temperature of the machine was maintained at 
37oC+0.5oC with thermostatic heater.    
Six tablets of each sample were placed 
into the basket rack assembly and placed into the 
beaker containing the disintegration medium and 
hung on the metal holder. The machine was placed 
in position and the basket oscillated in an upward 
and downward manner until the tablets fragmented. 
The time taken for each tablet to break into 
fragments was recorded and the average time 
calculated. 
 
Determination of Wavelength of Maximum 
Absorption (λmax)                    
For determination of λmax, 4.0cm3 of 
5µgcm-3 solution of the ciprofloxacin 
hydrochloride standard solution was taken into a 
1cm quartz cell and placed in the sample 
compartment of the UV/Visible spectrophotometer 
(model UV 757 GRT B – BRAW Scientific 
Instrument Company, England). The solution was 
scanned between 200nm – 500nm wavelength to 
obtain the absorption spectrum. 
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Preparation of Calibration curve  
A 4.0cm3 standard solution of 
Ciprofloxacin hydrochloride of various 
concentrations were taken in quartz cell and placed 
in the sample compartment of UV/Vis 
spectrophotometer and the machine was set at the 
obtained λmax (wavelength) of 276nm. The 
absorbance of each solution (i.e. 
1,2,3,4,5,6,7,8,9,10) µgcm-3 were taken in triplicate 
and recorded. The average value of the absorbance 
was taken and a calibration curve was plotted. A 
regression equation was obtained from the plot. 
The calibration curve regression equation was used 
to calculate the percentage concentration of each 
test sample solution. 
 
Assay for Ciprofloxacin Hydrochloride tablet  
The weight of twenty (20) tablets of each 
sample was taken and average weight noted. The 
weighed tablets were crushed into fine powder 
using pestle and mortar.  
A 0.006g of the powder was weighed and 
transferred into a 1000cm3 volumetric flask. 50cm3 
of water was added and shaken for 30 minutes 
mechanically to attain complete dissolution. The 
volume was made up to 1000cm3 mark in 
volumetric flask with distilled water. The solution 
was filtered and the absorbance taken at 
wavelength of 276nm using UV spectrophotometer 
(Adepoju, 2010).  
 
Sample Digestion  
To digest the sample, 2.00g of the 
powdered ciprofloxacin hydrochloride tablet of 
each sample was weighed and transferred into a 
round-bottom flask. The beaker used in weighing 
the powder was rinsed with 20cm3 of 5M 
trioxonitrate V acid and poured into the flask. 
Additional 30cm3 of the acid was transferred into 
the content of the round bottom flask and refluxed 
at 80oC for one hour on a thermostatically 
controlled heating mantle. The solution was 
allowed to cool to room temperature and made up 
to 100cm3 mark with deionized water. This was 
filtered with no. 42 Whatman filter paper and 
stored in a clean dry plastic sample bottle. The 
digested sample was aspirated into the atomic 
absorption spectrophotometer (AAS, Bulk 
scientific model 216VGP) at the individual metal 
wavelength and the absorbance values were 
recorded against a blank. Calibration curves for the 
different metals were plotted from metal standard 
solutions and from the result the concentrations of 
metals were calculated (Alsante et al., 2004). 
 
RESULTS AND DISCUSSION 
The results of the physicochemical 
properties with respect to the sample weights, 
disintegration time,    friability and percentage 
concentration for the various brands of 
ciprofloxacin hydrochloride tablets analysed are 
presented in Table 1.0 
 
Table 1.0: The Physicochemical and quantitative results obtained for twenty samples of 
      Ciprofloxacin hydrochloride tablets. 
Sample Average Weight 
of Tablet in     
Gram + SD 
Disintegration 
Time (minutes) + 
SD 




  A   0.6061+0.01   5.70  + 0.01   0.23+0.00   100.93+0.01 
  B   0.7663+0.00   4.55 + 0.05   0.09+0.01   99.07+ 0.09 
  C   0.6902+0.01   16.0. + 0.55   0.30+0.00   91.84+ 0.47 
  D   0.9645+0.01   5.00 + 0.03   0.10 +0.01   105.59+0.24 
  E   0.8445+0.00   6.42 + 0.05   0.40 +0.00   111.66+0.57  
  F   0.7750+0.00   4.17 + 0.07   0.25+ 0.01 . 106.53+0.30 
  G   0.7842+0.00   3.37+ 0.11   0.22+ 0.00   102.56 +0.11 
  H   0.7771+0.00   1.72 + 0.20   0.01 +0.01   106.76+ 0.31 
  I   1.0566+0.01   2.50+ 0.16   0.05+ 0.01   103.96+0.16  
  J    0.6920+0.01   3.67 + 0.10   0.72+ 0.02   102.33+0.10 
  K    0.9392+0.01   13.12 +0.40   0.21+ 0.00   99.53 +.0.07 
  L   0.6599+0.01   4..25+ 0.07   0.09+ 0.01   87.65+ 0.70 
  M   0.9900+0.01   2.33 + 0.17   0.60+ 0.01   108.39+0.39 
  N   0.7840+0.00   2.08+ 0.18   0.35 +0.00   109.09+0.44 
  O   0.9465+0.01   5.17+ 0.02   0.38+ 0.01   98.32 +  0.13 
  P   0.6994+0.01   4.67+ 0.04   0.03 +0.01   99.16 + 0.09 
  Q   0.8996+0.00   4.37+ 0.06   0.14 +0.00   97.90 + 0.20 
  R   0.8718+0.00   6.92+ 0.08   0.29 +0.00   98.18 + 0.14 
  S   0.7814+0.00   7.78+ 0.12   0.72 +0.02   98.18 + 0.14 
  T   0.7985+0.00   6.00 + 0.03   0.11 + 0.01 
 
  90.44 + 0.55 
  BP 
 Limit 
    15.00    1.00   90.00-110.00 
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The wavelength of maximum absorption 
(ʎmax) exhibited by the ciprofloxacin 
hydrochloride standard, Fig.1.0, was an indication 
that the ciprofloxacin standard was 99.80% pure, 
(Adepoju, 2010). The linear plot of the calibration 
curve, (Fig.2.0) indicated that ciprofloxacin obeys 
Beer-Lambert law.  
The uniformity of weight determination for 
all the samples showed compliance with the official 
specifications (BP, 2005) as none of the samples 
deviated by up to 5% from their mean (Table 1.0). 
This indicated that the weights of the tablets in 
each batch within each sample are within the 
expected official specifications.  
Similarly, all the samples gave less than 
1.0% w/w loss in weight with the friability test 
determination and within the official limit of 1.0% 
(Fig. 3.0, Table 1.0), (BP, 2005, USP, 2004). High 
value of friability could result to loss of tablet 
weight there by lowering the concentration of the 
















































































Fig. 3.0: Bar Chart of Mean Friability of Samples                         
 
All the samples passed the disintegration 
time test except sample C (Fig. 4.0) which fall 
outside the official limit of 15 minutes. This may 
be due to excess binder and pressure applied to the 
tablet during compressing that delayed its 
dissolution and would result in delaying its 
absorption when taken (BP, 2005). 
The assay of ciprofloxacin hydrochloride 
indicated that eighteen samples gave values that 
conform to the USP (2010) specification of 90 – 
110% w/w while sample E was above the limit 
with the value 111.66+0.53%w/w, sample L was 
below the limit with the value 87.65+0.698% w/w, 
(Table 1.0). These indicated that samples E   and L 
can be regarded as substandard and fake 
respectively, since neither can provide the required 
concentration needed for effective pharmacological 
activities. The reasons for high and low result seen 
in samples E and L respectively may be due to 
excess of 1% of active ingredient added to take 
care of loses and improper mixing of the wet 
granules during processing (Susmita et al., 2009).  
The calcium level in all the samples ranged 
between 0.006mg/g – 0.016mg/g, (Table 2.0) and 
falls within the specification of 3mg/g for the drug. 
The level of calcium in the product results from the 
nature of the excipient used which is usually 
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The sodium level in all the samples ranged 
between 0.012mg/g – 1.975mg/g (Table 2.0) and 
falls within the specification of 23.4mg/g, Webiner 
(2010) which must have been incorporated as a 
result of sodium methyl hydroxybenzoate, sodium 
propyl hydroxybenzoate and sodium benzoate used 
as preservatives, (Onlinelibrary, 2011).  
Copper levels were found to be within 
specification 0.25mg/g (Table 2.0) and must have 
been sourced mostly from the water and processing 
vessels, (Webiner 2010). Iron and zinc levels were 
also found to be within specification and that the 
only major source being the processing equipment, 
(FDA, 2002; BP, 2005),  
The potassium level in all the samples was 
within the limit specified by the official standard, 
3.6mg/g (table 2.0) with the major source coming 
from the commonly used preservative, potassium 
sorbate (Onlinelibrary, 2011).  The level of 
potassium in some of the samples ranged between 
0.071 – 0.214mg/g while in samples B, J and Q the 
potassium concentration was below the detection 
limit.  
Manganese concentration was found to be within 
the official limits in some samples, 0.25mg/g  
(Table 2.0), (IAPT, 1997) though in 14 of the 
samples the manganese concentration was below 
the detection limit. The manganese contents could 
come as impurities in the raw materials and the 
processing equipment.   
Lead concentrations in some of the samples 
were found above the official limits of 0.001mg/ 
with the highest concentration found in sample Q 
(Table 2.0, Fig.5.0). The major source of lead in 
pharmaceutical products have been related to the 
nature of the water used in the manufacturing 
process (Webiner 2010).    
After computing the t-test for both 
Africa/Europe it was observed that at 5% 
probability and 6 degrees of freedom, the table t-
test (t Critical one-tail) value was 2.44691 and the 
calculated t-test (t Stat) value was 0.43418 (Table 
3.0). This shows that the calculated t value was less 
than the table t-value, thus, it can be suggested that 
there was no significant difference between 
samples from the two continents.  
 For Africa/Asia at 5% probability and 10 
degrees of freedom, the calculated t-value 
(1.11759) was less than t-value (1.81246). This 
indicated that there was no significant difference 
between samples from the two continents (Table 
4.0). 
For Europe/Asia, at 5% probability and 12 degrees 
of freedom, the calculated t-value (2.2317) was 
greater than the table t-value (1.78229). This 
indicated a significant difference between samples 
from these continents, (Table 5.0). 
In the determination of the effect of temperature on 
the absorbance of ciprofloxacin hydrochloride, it 
was observed that there was no effect since the 
melting point of the compound is 318-3200C 
(Chemblink, 2011). 
The pH in both acidic and basic medium does not 
show any effect on the absorption of ciprofloxacin 
hydrochloride since it remained unionized in both 
basic and acidic medium being an acidic drug (Rui 
et al., 2003).  
The ionic strength of the solution does not have any 
effect on absorption properties of the ciprofloxacin 
hydrochloride solution. This is an indication that 
ciprofloxacin hydrochloride does not form complex 
with sodium ion (Na+) or that only divalent and 
trivalent metal ions form complexes (Gammeira et 


























Table 2.0: Concentration of Elemental Impurities (mg/g) in Ciprofloxacin 
Hydrochloride Tablets 
Sample Elements Concentration in mg/g 
   Ca  Na Cu  Fe  K Mn Pb Zn  
A  0.010  0.012 0.001 
     
0.026  
0.071 ND ND 0.007 
B  0.006  0.302 0.001 
     
0.028  
ND 0.013 0.001 0.007 
C  0.049  0.652 0.001 
     
0.030  
0.071 0.013 0.001 0.004 
D  0.010  0.411 0.001 
     
0.024  
0.071 0.013 ND 0.002 
E  0.013  0.409 0.001 
     
0.015  
0.213 ND ND 0.004 
F  0.010  0.471 0.001 
     
0.026  
0.143 ND ND 0.002 
G  0.016  1.975 0.001 
     
0.019  
0.214 ND ND 0.007 
H   0.013  0.691 0.001 
     
0.056  
0.214 ND ND 0.007 
I   0.100  0.504 0.001 
     
0.002  
0.071 ND ND 0.004 
J   0.016  0.385 0.001 
     
0.013  
ND ND ND 0.002 
K  0.010  0.572 0.001 
      
0.017  
0.071 0.001 ND 0.004 
L  0.010  0.481 ND 
      
0.011  
0.142 ND ND 0.002 
M  0.010  0.385 0.001 
      
0.030  
0.071 ND ND 0.004 
N   0.006  0.403 0.001 
      
0.026  
0.071 ND 0.001 0.002 
O   0.013  0.739 0.001 
      
0.050  
0.071 ND ND 0.002 
P   0.006  0.802 0.001 
      
0.013  
0.143 0.001 ND 0.002 
Q   0.006  0.554 0.001 
      
0.048  
ND 0.013 0.009 0.002 
R   0.009  0.676 0.001 
      
0.028  
0.143 ND ND 0.004 
S   0.006  0.802 ND 
      
0.013  
0.071 ND ND 0.002 
T   0.006  0.700 0.001 
      
0.030  
0.071 ND ND 0.004 
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Table: 3.0. t-test for samples from Europe and Africa 
t-Test: Two-Sample Assuming Unequal Variances 
     Europe Africa 
Mean 103.903 102.603 
Variance 4.14789 47.4992 
Observations 4 6 
Hypothesized Mean Difference 0 
 Df 6 
 t Stat 0.43418 
 P(T<=t) one-tail 0.33967 
 t Critical one-tail 1.94318 
 P(T<=t) two-tail 0.67934 
 t Critical two-tail 2.44691   
 
Table: 4.0. t-test for samples from Africa and Asia 
t-Test: Two-Sample Assuming Unequal Variances 
     Africa Asia 
Mean 102.603 98.684 
Variance 47.4992 43.8224 
Observations 6 10 
Hypothesized Mean Difference 0 
 Df 10 
 t Stat 1.11759 
 P(T<=t) one-tail 0.14494 
 t Critical one-tail 1.81246 
 P(T<=t) two-tail 0.28987 
 t Critical two-tail 2.22814   
 
 
Table: 5.0. t-test for samples from Europe and Asia 
t-Test: Two-Sample Assuming Unequal Variances 
     Europe Asia 
Mean 103.903 98.684 
Variance 4.14789 43.8224 
Observations 4 10 
Hypothesized Mean Difference 0 
 Df 12 
 t Stat 2.2417 
 P(T<=t) one-tail 0.02233 
 t Critical one-tail 1.78229 
 P(T<=t) two-tail 0.04466 
 t Critical two-tail 2.17881   
 


























   













Fig. 5.0: Mean Concentration of Lead in Ciprofloxacin Hydrochloride Tablet  
 
RECOMMENDATION  
Further work should be carried out using 
high performance liquid chromatography (HPLC) 
or gas chromatography mass spectrophotometer 
(GC-MS) and compare the result with that of the 
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